According to a research collaboration among UCLA investigators and Merck KGaA, berzosertib has shown promise for Covid-19 and is also being touted for the drug’s unusually broad effect in treating a range of cancers.
FUJIFILM selected the town of Holly Springs, North Carolina, as the company’s spot to build the largest cell culture biopharmaceutical production facility in North America.
The U.S. Federal Trade Commission (FTC) formed a multinational working group to evaluate pharmaceutical mergers.
Evofem Biosciences Inc. announced the launch of “Get Phexxi”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of the company’s non-hormonal, use-it-only-when-you-need-it birth control method, Phexxi (lactic acid, citric acid and potassium bitartrate).
Sandoz, a division of Swiss-based Novartis, inked a deal to buy U.K.-based GlaxoSmithKline’s cephalosporin antibiotics business.
Biohaven Pharmaceuticals’ third-generation prodrug troriluzole did not show a statistical improvement for patients when compared to those on placebo at the 48-week marker as a symptomatic treatment in mild-to-moderate Alzheimer’s disease (AD).
Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.
Enalare Therapeutics Inc., dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced the completed formation of the clinical stage biopharmaceutical company’s scientific advisory board.
Life sciences mergers and acquisitions (M&A) activity totaled $159 billion in 2020, down from $306 billion in 2019, reaching one of the lowest levels since 2014, according to the 2021 EY M&A Firepower report
A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.
